What is HC Wainwright’s Forecast for CRVS Q2 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for shares of Corvus Pharmaceuticals in a research report issued on Friday, May 15th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.17) per share for the quarter, down from their previous estimate of ($0.14). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.66) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.12) EPS, FY2027 earnings at ($0.63) EPS and FY2028 earnings at ($0.25) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01).

CRVS has been the subject of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Friday, March 13th. Barclays upped their target price on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Weiss Ratings raised Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 29th. Wall Street Zen cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Mizuho set a $30.00 target price on Corvus Pharmaceuticals in a research report on Thursday, January 29th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.33.

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS opened at $12.21 on Tuesday. The stock has a 50-day simple moving average of $15.07 and a 200-day simple moving average of $13.18. The stock has a market cap of $1.03 billion, a P/E ratio of -23.48 and a beta of 0.94. Corvus Pharmaceuticals has a 1 year low of $3.38 and a 1 year high of $26.95.

Institutional Trading of Corvus Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its position in shares of Corvus Pharmaceuticals by 481.7% in the 1st quarter. The Manufacturers Life Insurance Company now owns 101,779 shares of the company’s stock valued at $1,489,000 after purchasing an additional 84,282 shares during the period. Quantinno Capital Management LP purchased a new stake in Corvus Pharmaceuticals during the 1st quarter valued at approximately $336,000. Commodore Capital LP purchased a new stake in Corvus Pharmaceuticals during the 1st quarter valued at approximately $33,045,000. Spruce Street Capital LP purchased a new stake in Corvus Pharmaceuticals during the 1st quarter valued at approximately $3,388,000. Finally, Renaissance Technologies LLC purchased a new stake in Corvus Pharmaceuticals during the 1st quarter valued at approximately $1,190,000. 46.64% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Corvus Pharmaceuticals

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Neutral Sentiment: HC Wainwright maintained a Buy rating on Corvus Pharmaceuticals and reiterated a $27 price target, signaling continued long-term confidence despite lower earnings assumptions.
• Positive Sentiment: The firm’s price target remains well above the current trading range, which may support investor expectations for upside if the company executes on its pipeline and clinical milestones.
• Negative Sentiment: HC Wainwright lowered EPS estimates for FY2026, FY2027, FY2028, and several quarterly periods, reflecting a more conservative outlook on Corvus Pharmaceuticals’ near- and medium-term earnings trajectory. Article Title

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.